

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 31/66		A3	(11) International Publication Number: WO 99/04773 (43) International Publication Date: 4 February 1999 (04.02.99)
(21) International Application Number: PCT/US98/14796		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 17 July 1998 (17.07.98)			
(30) Priority Data: 60/053,351 22 July 1997 (22.07.97) US 60/053,535 23 July 1997 (23.07.97) US 9717590.5 20 August 1997 (20.08.97) GB 9717850.3 22 August 1997 (22.08.97) GB			
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): DAIFOTIS, Anastasia, G. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). SANTORA, Arthur, C., II [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). YATES, A., John [GB/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(88) Date of publication of the international search report: 15 April 1999 (15.04.99)	
(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).			

(54) Title: METHOD FOR INHIBITING BONE RESORPTION**(57) Abstract**

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein. The compounds are bisphosphonates selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, optionally in combination with a histamine H₂ antagonist.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/14796

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SINGER F R ET AL: "Bisphosphonates in the treatment of disorders of mineral metabolism."</p> <p>ADVANCES IN ENDOCRINOLOGY AND METABOLISM, (1995) 6 259-88. REF: 109 JOURNAL CODE: CB4. ISSN: 1049-6734., XP002092145</p> <p>United States</p> <p>see page 260, paragraph 2 - page 267, paragraph 3; figure 1</p> <p>see page 273, paragraph 3 - page 276, paragraph 3</p> <p>---</p> <p>-/-</p>	1-28, 30-33

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

A. Jakobs

INTERNATIONAL SEARCH REPORT

onational Application No
PCT/US 98/14796

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIBERMAN U A ET AL: "EFFECT OF ORAL ALENDRONATE ON BONE MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS" THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 333, no. 22, 30 November 1995, pages 1437-1443, XP000579307 see abstract ---	1-28, 30-33
X	BANKHURST A ET AL: "THREE-YEAR TREATMENT WITH ALENDRONATE PREVENTS FRACTURES IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS" ARTHRITIS AND RHEUMATISM, vol. 38, no. 9, SUPPL, 1 September 1995, page S359 XP000579368 see abstract ---	1-28, 30-33
X	FILIPPONI P ET AL: "CYCLICAL CLODRONATE IS EFFECTIVE IN PREVENTING POSTMENOPAUSAL BONE LOSS: A COMPARATIVE STUDY WITH TRANSCUTANEOUS HORMONE REPLACEMENT THERAPY" JOURNAL OF BONE AND MINERAL RESEARCH, vol. 10, no. 5, May 1995, pages 697-703, XP002042531 see abstract ---	1,2,6,7, 12,13, 30-33
X	MCCLUNG M R ET AL: "Tiludronate therapy for Paget's disease of bone 'published erratum appears in Bone 1996 Mar;18(3):292!.'" BONE, (1995 NOV) 17 (5 SUPPL) 493S-496S. JOURNAL CODE: ASR. ISSN: 8756-3282., XP002092146 United States see abstract ---	1,2,6,7, 12,13, 30-33
X	SELTENMEYER, Y. ET AL: "A comparison of the antiresorptive potency of various bisphosphonates in vivo with their inhibitory effect in vitro on squalene synthase and cellular sterol synthesis." BONE (NEW YORK), (1997) VOL. 20, NO. 4 SUPPL., PP. 114S. MEETING INFO.: 25TH EUROPEAN SYMPOSIUM ON CALCIFIED TISSUES HARROGATE, ENGLAND, UK APRIL 25-29, 1997 ISSN: 8756-3282., XP002092147 see abstract ---	1,2,6,7, 12,13, 30-33

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 98/14796

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ADACHI J.D.: "osteoporosis-Its Diagnosis, Management and Treatment with New Oral Bisphosphonate Agent, Etidronate" TODAY'S THERAPEUTIC TRENDS, vol. 14, no. 1, 1996, pages 13-24, XP002092148 see abstract see page 19, paragraph 2 - page 21, paragraph 5 ---	1-28, 30-33
X	BELL, NORMAN H. ET AL: "Bisphosphonates in the treatment of osteoporosis" ENDOCRINE (1997), 6(2), 203-206 CODEN: EOCRE5; ISSN: 1355-008X, XP002092149 see abstract ---	1-28, 30-33
X	EP 0 274 158 A (NORWICH EATON PHARMA) 13 July 1988 see claims 1-24; examples 1-8; table 1 ---	1-28, 30-33
X	WO 94 00129 A (PROCTER & GAMBLE PHARMA) 6 January 1994 see claims 1-10; example 5 ---	1-28, 30-33
X	WO 95 08331 A (MERCK FROSST CANADA INC ; BECHARD SIMON R (CA)) 30 March 1995 see page 3, line 13 - page 5, line 23 ---	1-28, 30-33
X	WO 95 28936 A (MERCK & CO INC ; YATES ASHLEY J (US)) 2 November 1995 see abstract -----	1-28, 30-33

INTERNATIONAL SEARCH REPORT

rnational application No.

PCT/US 98/ 14796

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-29, 33 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

In view of the large number of compounds, which are defined by the general definition(s)/formulae used in claims 1,6,7,12,13,18-30,32-33 the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and / or the compounds mentioned in the claims, and to the general idea underlying the application. (see Guidelines, chapter III, paragraph 2.3)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/14796

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0274158	A 13-07-1988	AU 616391 B		31-10-1991
		AU 8269487 A		23-06-1988
		CA 1321198 A		10-08-1993
		DE 3789436 D		28-04-1994
		DE 3789436 T		25-08-1994
		DK 670487 A		20-06-1988
		IE 61881 B		30-11-1994
		JP 63239291 A		05-10-1988
		KR 9601845 B		06-02-1996
		PH 26154 A		18-03-1992
		US 5519013 A		21-05-1996
		US 5071840 A		10-12-1991
		US 5334586 A		02-08-1994
		ZA 8709454 A		10-06-1988

WO 9400129	A 06-01-1994	AT 161423 T		15-01-1998
		AU 659329 B		11-05-1995
		AU 4403893 A		24-01-1994
		CA 2138367 A,C		06-01-1994
		DE 69316013 D		05-02-1998
		DE 69316013 T		09-07-1998
		DK 648120 T		19-01-1998
		EP 0648120 A		19-04-1995
		ES 2111163 T		01-03-1998
		GR 3025792 T		31-03-1998
		HU 70210 A		28-09-1995
		JP 7508278 T		14-09-1995
		NO 945058 A		28-02-1995

WO 9508331	A 30-03-1995	US 5431920 A		11-07-1995
		AU 681700 B		04-09-1997
		AU 7735794 A		10-04-1995
		CA 2170537 A		30-03-1995
		EP 0720480 A		10-07-1996
		JP 9504276 T		28-04-1997

WO 9528936	A 02-11-1995	US 5646134 A		08-07-1997
		AU 2374895 A		16-11-1995
		BG 100910 A		31-03-1998
		CA 2188030 A		02-11-1995
		CN 1146152 A		26-03-1997
		CZ 9603055 A		11-06-1997
		EP 0756483 A		05-02-1997
		FI 964213 A		18-10-1996
		HR 950239 A		30-04-1997
		HU 74911 A		28-03-1997
		JP 9512268 T		09-12-1997
		NO 964441 A		18-10-1996
		PL 318552 A		23-06-1997
		SK 133396 A		07-05-1997
		ZA 9503185 A		27-12-1995